New Drug Approved by FDA to Treat Acute Myelogenous Leukemia
The U.S. Food and Drug Administration has approved Agios Pharmaceuticals’ Idhifa (enasidenib) to treat acute myelogenous leukemia.
FDA Approves First Subcutaneous Therapy to Treat HAE
The U.S. Food and Drug Administration has approved CSL Behring’s Haegarda (C1 esterase inhibitor subcutaneous [human]), the first and only subcutaneous therapy indicated for routine prophylaxis to prevent hereditary angioedema attacks in adolescent and adult patients.
CSL Behring ’s Privigen Now Approved to Treat CIDP
The U.S. Food and Drug Administration (FDA) has approved Privigen (immune globulin intravenous [human] 10% liquid) to treat adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability.
Congress Passes Bills Extending CHIP Funding
The House Energy and Commerce Committee and the Senate Finance Committee passed bills to extend for five years the federal funding forChildren’s Health Insurance Program.
CSL Behring Awards LEAD Grants to Support Patient Rights
CSL Behring has awarded three U.S. bleeding disorder patient organizations Local Empowerment for Advocacy Development (LEAD) grants to help them ensure patients’ voices continue to be heard in their state capitals on legislative and public policy issues.
FDA Approves Mavyret to Treat Adults with Chronic Hepatitis C
The U.S. Food and Drug Administration has approved AbbieVie Inc.’s Mavyret (glecaprevir and pibrentasvir) to treat adults with certain types of hepatitis C.
Clinical Trial of Universal Flu Vaccine Is a Success
Scientists at the National Institutes of Health, Frederick National Laboratory for Cancer Research and the University of Melbourne in Australia tested a new universal flu vaccine that produced good immunity against several different strains of influenza viruses.
New Rules Narrow ACA’ s Contraception Mandate
New rules issued by the U.S. Department of Health and Human Services give employers more leeway to withhold birth control coverage on religious grounds.
Study Shows Impact of Age and Pre-Existing Influenza Immune Responses in Older and Younger Adults
In an effort to understand how current influenza vaccines are influenced by preexisting immunity in people of different ages, researchers vaccinated volunteers ages 18 years to 85 years with split, inactivated Fluzone influenza vaccine in four consecutive seasons from 2013 to 2016, and assessed the impact of repeated vaccination on breadth and durability of antibodies as a result of vaccine strain changes.
Study Shows a Positive Mood Could Boost Effectiveness of Flu Vaccine
Researchers at the University of Nottingham in England have found evidence that being in a positive mood when receiving an influenza (flu) vaccine can increase its protective effect.